Temelimab

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameTemelimab
Drug Alias NameAnti-HERV-W humanized monoclonal antibodies (GeNeuro)GNN-001GENHP-01GNbAC-1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionRecombinant envelope protein inhibitorsToll like receptor 4 antagonists
TargetsRecombinant envelope proteinToll like receptor 4
Therapy Area/IndicationsPost-Acute COVID-19 SyndromeDiabetes Mellitus, Type 1Multiple Sclerosis, Relapsing-Remitting +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaUkraine +[15] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGeneuro Sa
China Registration ClassN/A

Develop Information

Active CompaniesGeneuro Innovation SasGeneuro Sa
Inactive CompaniesGeneuro Australia Pty Ltd
Active IndicationsPost-Acute COVID-19 SyndromeMultiple Sclerosis
Inactive IndicationsDiabetes Mellitus, Type 1Multiple Sclerosis, Relapsing-Remitting

Other Information

ATC CodeN/A
Related LinksN/A